Boehringer's Ofev Nears EU Approval for Systemic Sclerosis-Related Lung Disease
Key Insights
The EMA's CHMP (search) has recommended approval of Ofev (nintedanib) as the first treatment for systemic sclerosis-related interstitial lung disease (search) in the EU, marking a significant advancement for this rare condition.
Ofev demonstrated strong market performance with sales reaching €677 million in H1 2019, representing a 22% growth primarily from its established use in idiopathic pulmonary fibrosis (search).
With systemic sclerosis (search) affecting approximately 2.5 million people worldwide and lung disease accounting for 35% of related deaths, this approval could significantly impact patient care.
Boehringer Ingelheim's respiratory drug Ofev (nintedanib) has received a positive recommendation from the European Medicines Agency (search)'s Committee for Medicinal Products for Human Use (search) (CHMP (search)) for treating adults with systemic sclerosis-related interstitial lung disease (search) (SSc-ILD (search)), positioning it to become the first approved therapy for this indication in the EU.
The recommendation marks a crucial milestone in addressing an significant unmet medical need. SSc-ILD (search), a manifestation of systemic sclerosis (search) (also known as scleroderma (search)), is characterized by progressive fibrosis of the lungs and other organs, significantly impacting patient survival and quality of life.
Disease Burden and Current Treatment Landscape
Systemic sclerosis (search) affects approximately 2.5 million people globally, with lung involvement being particularly devastating. Pulmonary complications represent the leading cause of mortality, accounting for nearly 35% of scleroderma (search)-related deaths. Currently, there is no curative treatment available, with management primarily focused on symptom alleviation through phototherapy, physiotherapy, and corticosteroids.
Commercial Impact and Market Position
Ofev has already established a strong market presence through its approved indication for idiopathic pulmonary fibrosis (search) (IPF (search)). The drug demonstrated robust commercial performance, with sales growing 22% to reach €677 million ($751 million) in the first half of 2019. Market analysts suggest that the potential market for SSc-ILD (search) could rival that of IPF, indicating significant growth opportunities for Boehringer Ingelheim.
Competitive Landscape
The development pipeline for scleroderma (search) treatments remains notably sparse. Swedish biotech Vicore Pharma (search)'s VP01, currently in phase 2 trials for both scleroderma and IPF (search), represents the only near-term potential competitor to Ofev in this space. This limited competition potentially positions Boehringer Ingelheim to maintain a dominant position in the SSc-ILD (search) treatment landscape.
Regulatory Context
The positive CHMP (search) opinion follows Ofev's approval for SSc-ILD (search) in the United States last year. This recommendation typically precedes formal European Commission approval, which would make the treatment available to patients across the European Union. The expansion into SSc-ILD represents a significant advancement in the management of this challenging condition, offering hope to patients who previously had limited therapeutic options.